WHY THE NATION MUST INVEST IN HERBAL MEDICINE DEVELOPMENT

Research needs in the field of herbal medicines are huge, but are balanced by the potential health
benefits and the enormous size of the market. Research into the quality, safety, molecular effects,
and clinical efficacy of the numerous herbs used in Ghana is needed. Newly emerging scientific
techniques and approaches such as Genomic testing and chemical fingerprinting techniques
using hyphenated testing platforms are now available for definitive authentication and quality
control of herbal products.

Through the Medical Training and Research Act, 2010, the Centre for Plant Medicine
Research (CPMR) was established for the promotion of scientific research, knowledge and
development in the field of plant medicine in Ghana. The object of the Centre is to research into
plant medicine for the promotion, encouragement, regulation, extension, transfer and application
of scientific research knowledge and development in the field of plant medicine . The funds of the
Centre include moneys provided by Parliament, fees and charges accruing to the Centre in the
performance of its functions, donations, grants and gifts, and any other moneys that are approved
by the Minister responsible for Finance. In addition, the Centre may retain a percentage of
internally generated funds realised in the performance of its functions. However, the percentage
retained by the Centre shall be as specified by the Minister responsible for Finance.

This notwithstanding, the Centre has not received the needed attention by the managers of the
country. In 1990, expenditure associated with “alternative” therapy in the United States was
estimated to be US$13.7 billion. This had doubled by the year 1997, with herbal medicines
growing faster than any other alternative therapy. In Australia, Canada, and the United Kingdom,
annual expenditure on traditional medicine is estimated to be US$80 million, US$1 billion, and
US$2.3 billion, respectively. These figures reflect the incorporation of herbal and other forms of
traditional medicine into many health care systems and its inclusion in the medical training of
doctors in many parts of the developed world. The total commercial value of the herbal
medicines market cannot be ignored. For example, in 1995, the total turnover of non-
prescription-bound herbal medicines in pharmacies was equal to almost 30% of the total turnover
of non-prescription-bound medicines in Germany, and in the United States, the annual retail
sales of herbal products was estimated to be US$5.1 billion. In China, the total value of herbal
medicine manufactured in 1995 reached 17.6 billion Chinese yuan (approximately US$2.5
billion). This trend has continued, and annual revenues in Western Europe reached US$5 billion
in 2003–2004. In China, sales of herbal products totalled US$14 billion in 2005, and revenue
from herbal medicines in Brazil was US$160 million in 2007. It is estimated that the annual
worldwide market for these products approached US$60 billion in 2008.

Regardless of why an individual uses it, herbal medicine provides an important health care
service whether people have physical or financial access to allopathic medicine, and it is a
flourishing global commercial enterprise that Ghana can take advantage of.
Evidence for the potential protective effects of selected herbs is generally based on experiments
demonstrating a biological activity in a relevant in vitro bioassay or experiments using animal
models. In some cases, this is supported by both epidemiological studies and a limited number of
intervention experiments in humans. However, the logistics, time, and cost of performing large,
controlled human studies on the clinical effectiveness of an herb are prohibitive, especially if the
focus is on health promotion. Therefore, there is an urgent need to develop new biomarkers that
more clearly relate to health (and disease) outcomes. Furthermore, research is needed to meet the
challenges of identifying the active compounds in the plants, as well as research-based evidence
on whether whole herbs or extracted compounds are better.

The issue of herb–herb and herb–drug interactions is also an important one that requires
increased awareness and study, as polypharmacy and polyherbacy are common. The use of new
technologies, such as nanotechnology and novel emulsification methods, in the formulation of
herbal products, which affects their bioavailability and the efficacy, is the way forward. The
Centre for Plant Medicine Research needs to be resourced adequately to meet the growing needs
of herbal medicine development across the globe. This should elevate the CPMR to a level where
it can pursue ISO certification and remain a force to reckon with when it comes to the research
and development of herbal medicines across the West African sub-region.

Investment should be made in Smart screening methods and metabolic engineering, which offer
exciting technologies for new natural product discovery. Advances in rapid genetic sequencing,
coupled with manipulation of biosynthetic pathways, may provide a vast resource for the future
discovery of pharmaceutical agents. This can lead to reinvestigation of some agents that failed
earlier trials and can be restudied and redesigned using new technologies to determine whether
they can be modified for better efficacy and fewer side effects. For example, maytansine isolated
in the early 1970s from the Ethiopian plant Maytenus serrata, looked promising in preclinical
testing but was dropped in the early 1980s from further study when it did not translate into
efficacy in clinical trials; later, scientists isolated related compounds, ansamitocins, from a
microbial source. A derivative of maytansine, DM1, has been conjugated with a monoclonal
antibody and is now in trials for prostate cancer.

In conclusion, herbal medicines have been used since the early days of humankind and are still
used throughout the world for health promotion and treatment of disease. Plants and natural
sources form the basis of today’s modern medicine and contribute largely to the commercial drug
preparations manufactured today. About 25% of drugs prescribed worldwide are derived from
plants. Still, herbs, rather than drugs, are often used in health care. For some, herbal medicine is
their preferred method of treatment. For others, herbs are used as adjunct therapy to conventional
pharmaceuticals.

Regardless of the reason, those using herbal medicines should be assured that the products they
are buying are safe and contain what they are supposed to, whether this is a particular herb or a
particular amount of a specific herbal component. Consumers should also be given science-based
information on dosage, contraindications, and efficacy. To achieve this, the CPMR should be
equipped adequately to meet the standards of global harmonization needed for the responsible
production and marketing of herbal medicines both locally and abroad. I believe when the
CPMR is given the attention that it deserves, Ghana will count her blessings, name them one by
one, and it will surprise us what Herbal Medicines have done and can do.

By MH/Dr Ernest Aggrey, 0543999776/donmirage77@yahoo.com

Reference:

Benzie, I.F. and Wachtel-Galor, S. (2011).Herbal medicine: Bimolecular and Clinical

Aspects, Herbal Medicine; An Introduction to Its History, Usage, Regulation, Current Trends,
and Research Needs. Second Edition; CRC Press. Pg 7-9